Fertility fatigue weighing on Alpha IVF shareholders
KUALA LUMPUR: When Alpha IVF Group Bhd delivered its initial public offering (IPO) in March last year at 32 sen per share, the mood was expectant, much like the clients it serves.
As a specialist in fertility treatments, Alpha IVF operates in a resilient, emotionally resonant niche of the healthcare sector, industry observers said.
The outlook seemed strong, with its compelling narrative and branding on point.
But fast forward a year, and the share price has dipped to around 28 sen, despite glowing brochures, media coverage and several investor briefings.
At midday today, the stock settled 1.75 per cent lower at 28 sen. Year-todate, it has shed 17.65 per cent or six sen.
The company may help create new life, but on Bursa Malaysia, investors are now asking why Alpha IVF is not breathing more life into its financial performance.
Administrative Costs: A Growing Burden
In its third quarter of financial year 2025, Alpha IVF reported a 12.4 per cent decline in net profit, even as revenue increased.
Why? A 76.4 per cent surge in administrative expenses, which ballooned to RM9.56 million, the observers said. These include staff costs, professional fees and other operating overheads.
The message to investors: revenues are growing, but profits are not keeping up.
Margins Under Pressure
From a net profit margin of 39 per cent in FY2023, Alpha IVF slipped to 32 per cent in FY2024.
In a high-stakes industry where precision and people matter, cost control is always tricky but the margin squeeze is triggering doubts about how scalable and efficient the business model truly is, the observers said.
Earnings Quality: Real or Just on Paper?
Another worry lies in the company's accrual ratio of 0.42. While Alpha IVF is profitable on paper, the ratio implies that a significant chunk of that profit isn't flowing into its coffers as cash, the observers said.
For discerning investors, strong cash flow is the bedrock of trust.
The fear? Profits without liquidity could mean trouble during expansion or downturns.
Lofty Valuation
With a current price-to-earnings (P/E) ratio of 26 times, Alpha IVF is trading above its estimated fair value of around 22.3 times.
The observers said that kind of premium demands near-flawless execution, and the company's recent numbers have not yet delivered the confidence to justify such a valuation.
Sentiment: From Excitement to Uncertainty
The observers said despite experienced doctors, high-tech labs and a vital social mission, Alpha IVF is grappling with what some call "fertility fatigue" - not among patients, but among shareholders.
The promise of a growing fertility market remains, but costs are rising, earnings quality is in question and the stock has been slow to excite post-listing.
Can Alpha IVF deliver? The observers said fertility is not just about hope - it's about timing and preparation.
"The same holds for markets. Alpha IVF has the expertise, branding and sector advantage. But to regain momentum, it must deliver stronger margins, healthier cash flow, and strategic clarity," one observer said.
Until then, it may continue to be the company that helps deliver babies, but not yet the financial results its shareholders were expecting, the observer added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
6 hours ago
- New Straits Times
PR frenzy, poor fundamentals: Disappointing IPO darlings
KUALA LUMPUR: Over the past 18 months, Bursa Malaysia witnessed a surge in new listings, many accompanied by high expectations and polished narratives. Behind the scenes, public relations consultants and investment advisors played pivotal roles organising media briefings, analyst meetings and investor briefings to generate interest and drive early demand. However, as the dust settles, some of these companies have fallen short of their promises, with share prices slipping below IPO levels despite the initial fanfare. Here are three companies that illustrate the disconnect between pre-listing optimism and post-listing realities: Alpha IVF Group Bhd •Recent Price: 28 sen (as of June 6) Alpha IVF, a fertility services provider, made its debut on Bursa Malaysia with a compelling narrative centred around expanding fertility awareness and clinical capabilities. The company positioned itself as a beacon of hope for couples struggling to conceive, backed by cutting-edge technologies and a regional footprint. Public relations consultants heavily promoted the IPO, emphasising emotional branding - stories of successful IVF journeys, warm imagery of smiling babies - and reassuring interviews with founders and doctors. Investor briefings were held, reinforcing the company's regional growth story. The IPO was oversubscribed, and the stock saw a slight uptick upon listing. However, the honeymoon phase was short-lived. Analysts began to question the valuation multiples, especially given the thin margins and rising operational costs of running fertility centres. The company's expansion plans, initially perceived as bold, began to look like expensive bets in a niche and price-sensitive market. Despite the promotional efforts, Alpha IVF's share price gradually declined, slipping below its IPO price and staying there. Notably, the IPO price of RM0.32 corresponded to a price-to-earnings (P/E) ratio of 21.92x, based on a net profit of RM54.79 million and earnings per share (EPS) of 1.46 sen for the financial year ended May 31, 2023. This valuation was higher than the industry's average P/E ratio, raising concerns about the company's valuation amidst the optimism. CPE Technology Bhd •IPO Price: RM1.07 •Recent Price: 71 sen (as of June 6) CPE's entry into Bursa was anything but quiet. As a precision engineering company with clients in the semiconductor, life sciences, and industrial automation sectors, it was touted as a proxy for Malaysia's high-tech ambitions. The IPO narrative leaned heavily on its global supply chain connections, particularly its exports to the US, Europe and China. In the weeks leading up to its listing, CPE's name was everywhere. PR consultants rolled out a carefully staged campaign: glossy investor kits were circulated, media interviews were arranged with top executives, and photos of high-tech assembly lines flooded financial pages. There were even organised tours for analysts and key fund managers to CPE's Johor-based facilities, complete with safety helmets, walkthroughs, and sales pitch presentations over coffee. The message was clear: CPE was not just another component maker - it was a growth story in a fast-evolving tech ecosystem. Investors initially responded with enthusiasm. The IPO was oversubscribed, and there was buzz about CPE being well-positioned to ride the next wave of industrial demand. But reality, as it often does, proved more complicated. Just a few quarters in, cracks began to appear. Order flows from major clients slowed as the global tech sector cooled. Margins came under pressure, not least due to rising raw material costs and a strong US dollar. Earnings missed early projections, and suddenly, the glow around CPE started to fade. The same analysts who had attended the factory tours began to revise their outlooks. Despite the polished communications campaign and well-managed listing strategy, CPE's share price drifted below its IPO level. The company had a credible story - but not enough momentum to keep the market convinced. DXN Holdings Bhd •IPO Price: 70 sen •Recent Price: 50 sen (as of June 6) DXN's return to the stock market after years in private hands was framed as a rebirth. PR consultants spoke of a "new chapter" for the direct-selling giant, with aggressive outreach to media and investor groups. Yet, cracks began to appear when earnings underwhelmed and overseas sales growth slowed. Despite the well-orchestrated relisting campaign, investors began to question whether DXN's golden era was behind it. Conclusion: Hype Fades, Fundamentals Remain Industry observers said new IPOs often arrive on a wave of excitement, backed by slick presentations, aggressive PR campaigns, and promises of untapped potential. But investors must learn to separate story from substance. Just because a stock is trending or being heavily marketed doesn't mean it's a good buy. PR blitzes can create temporary buzz, but they can't sustain valuations if earnings disappoint and growth stalls. The observers said the message is clear: don't get carried away by headlines or hype, and stick to fundamentals, scrutinise the financials and invest with discipline.
New Straits Times
28-05-2025
- New Straits Times
Fertility fatigue weighing on Alpha IVF shareholders
KUALA LUMPUR: When Alpha IVF Group Bhd delivered its initial public offering (IPO) in March last year at 32 sen per share, the mood was expectant, much like the clients it serves. As a specialist in fertility treatments, Alpha IVF operates in a resilient, emotionally resonant niche of the healthcare sector, industry observers said. The outlook seemed strong, with its compelling narrative and branding on point. But fast forward a year, and the share price has dipped to around 28 sen, despite glowing brochures, media coverage and several investor briefings. At midday today, the stock settled 1.75 per cent lower at 28 sen. Year-todate, it has shed 17.65 per cent or six sen. The company may help create new life, but on Bursa Malaysia, investors are now asking why Alpha IVF is not breathing more life into its financial performance. Administrative Costs: A Growing Burden In its third quarter of financial year 2025, Alpha IVF reported a 12.4 per cent decline in net profit, even as revenue increased. Why? A 76.4 per cent surge in administrative expenses, which ballooned to RM9.56 million, the observers said. These include staff costs, professional fees and other operating overheads. The message to investors: revenues are growing, but profits are not keeping up. Margins Under Pressure From a net profit margin of 39 per cent in FY2023, Alpha IVF slipped to 32 per cent in FY2024. In a high-stakes industry where precision and people matter, cost control is always tricky but the margin squeeze is triggering doubts about how scalable and efficient the business model truly is, the observers said. Earnings Quality: Real or Just on Paper? Another worry lies in the company's accrual ratio of 0.42. While Alpha IVF is profitable on paper, the ratio implies that a significant chunk of that profit isn't flowing into its coffers as cash, the observers said. For discerning investors, strong cash flow is the bedrock of trust. The fear? Profits without liquidity could mean trouble during expansion or downturns. Lofty Valuation With a current price-to-earnings (P/E) ratio of 26 times, Alpha IVF is trading above its estimated fair value of around 22.3 times. The observers said that kind of premium demands near-flawless execution, and the company's recent numbers have not yet delivered the confidence to justify such a valuation. Sentiment: From Excitement to Uncertainty The observers said despite experienced doctors, high-tech labs and a vital social mission, Alpha IVF is grappling with what some call "fertility fatigue" - not among patients, but among shareholders. The promise of a growing fertility market remains, but costs are rising, earnings quality is in question and the stock has been slow to excite post-listing. Can Alpha IVF deliver? The observers said fertility is not just about hope - it's about timing and preparation. "The same holds for markets. Alpha IVF has the expertise, branding and sector advantage. But to regain momentum, it must deliver stronger margins, healthier cash flow, and strategic clarity," one observer said. Until then, it may continue to be the company that helps deliver babies, but not yet the financial results its shareholders were expecting, the observer added.
The Star
22-04-2025
- The Star
Alpha IVF Group eyes regional expansion
The company's revenue for 3Q24 grew 12.2% to RM43.24mil. KUALA LUMPUR: Alpha IVF Group Bhd is targeting to operate a total of at least 15 facilities, covering Malaysia, Indonesia, China, the Philippines, and Singapore by the financial year ending May 31, 2027. The fertility care specialist currently operates four full-fledged IVF centres across Malaysia and Singapore, along with two sales and representative offices in China. For the next 12 months, Alpha IVF expects two additional IVF centres in Malaysia, two IVF centres in South East Asia and four satellite clinics in Indonesia will be operational, it said in a filing with Bursa Malaysia. In the third quarter ended Feb 28 (3Q25), Alpha IVF posted a lower net profit of RM11.9mil, or earnings per share of 0.24, compared with RM13.6mil, or 0.30 sen in the year-ago quarter. Revenue for the quarter stood at RM40.6mil against RM40.7mil posted last year. In the nine months to Feb 28, the group posted a net profit of RM41.4mil, up 6.3% from RM38.9mil a year ago, while revenue rose 5% to RM126.8mil from RM120.8mil previously. Alpha IVF attributed the improved performance primarily to continued growth in its foreign patient segment within its Malaysian operations during the period. The growing foreign patient base underscores Alpha IVF Group's strong regional presence and reputation for delivering world-class fertility care. 'As we move forward, our strategy remains consistent – to grow both organically via our existing centres and through regional expansion initiatives. 'We believe the steps we are taking to expand access to our fertility treatment services in the region will not only strengthen our regional presence but also deliver long-term value for our shareholders,' group managing director Datuk Dr Colin Lee Soon Soo said in a statement.
